Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pemefolacianine for Intraoperative Molecular Imaging of Lung Cancer
NCT07772895Phase 1Recruiting
- Start
- Mar 2026
- Primary completion
- Mar 2027
- Countries
- 1
01
Overview
Phase 1, open-label trial of pemefolacianine in lung cancer (2 cohorts). Primary endpoint: Number of participants with treatment-related adverse events as assessed by CTCAE v5.0 at 30 days. Started Mar 2026; status: recruiting.
02
Drugs
pemefolacianine
03
Conditions
lung cancer
Beyond the preview
Go deeper on NCT07772895.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07772895.